THIS IS MORE THAN HOPE
Patients diagnosed with non-Hodgkin lymphoma are told they’ll achieve remission with first-line chemotherapy. But about 50% of them don’t, as their cancer resists treatment after treatment. They are running out of options…and hope. They need a reason to believe complete remission can still exist after treatment failure. YESCARTA is the first CAR T-cell therapy approved for NHL. It can give appropriate 3rd-line patients something more than hope––it can give them a chance for complete remission. With a strategically choreographed ecosystem focused on messages of empowerment and hope, we are able to provide patients with the resources they need to fight for their survival.
Our goal was to give patients not only hope, but a chance for real remission. Together, with patients and oncologists, we are all succeeding.
SOCIAL THAT ARRESTS AND INSPIRES
YESCARTA Facebook ads are emotional, beautiful, and full of hope. Real patients share their stories of survival; they are natural and relatable, an authentic call to action. Branded posts maintain the raw emotion of the YESCARTA campaign, giving patients the empathy and encouragement they need to move forward.
AN OPPORTUNITY TO CONNECT: SOCIAL POSTS
THE POWER OF PATIENT SELF ADVOCACY
Despite a very small patient population, YESCARTA made an outsized impact. These numbers represent more than campaign results—they represent lives saved.
PATIENT POPULATION: 8,400
UNIQUE SITE VISITS